Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Urogenital Cancer Genitourinary Cancer—Kidney and Bladder

Genitourinary Cancer—Kidney and Bladder

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
 
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo,  et al.
Clinical trial information: NCT03635892
 
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
 
Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, et al.
 Clinical trial information: NCT03117309
 
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
 
Cristina Suarez Rodriguez, James Larkin, Poulam M. Patel, et al.
Clinical trial information: NCT02819596
 
Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.
 
Xinan Sheng, Dingwei Ye, Ai-Ping Zhou, et al.
Clinical trial information: NCT03095040
 
First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.
 
Luis A Meza, Nazli Dizman, Paulo Gustavo Bergerot, et al.
Clinical trial information: NCT03829111
 
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
  
Laurence Albiges, Martin H Voss, Brian I. Rini,  et al.
Clinical trial information: NCT02684006
 

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

Hamid Emamekhoo, Mark R Olsen, Bradley Curtis Carthon,  et al.
Clinical trial information: NCT02982954
 
Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.
 
Jaleh Fallah, Haley Gittleman, Chana Weinstock,  et al.
 
 
Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.
 
Samuel Aaron Funt, Michael Lattanzi, Karissa Whiting,  et al.
 Clinical trial information: NCT02989584
 
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
 
Petros Grivas, Jun Yin, Vadim S Koshkin, et al.
Clinical trial information: NCT03532451
 
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.
 
Thomas Powles, Daniel P. Petrylak, Se Hoon Park, et al.
These results are consistent with previously reported findings reported in the NEJM.  Clinical trial information: NCT02603432
 
POSTER SESSION:
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
 
Srikala S. Sridhar, Thomas Powles, Yohann Loriot, et al.
 Clinical trial information: NCT02603432